GLUCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Glucose Health, Inc.

Financials through Q3 FY2017, quarter ended Sep 30, 2017Last filing: 10-Q on Nov 14, 2017

$0.44+0.10 (+28.76%)

Close on Oct 19, 2026

Market cap: $1.82M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Sep 30, 2017

Glucose Health reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Glucose Health's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Glucose Health's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on Mar 30, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GLUC.

Revenue growth-70.6% · median -11.3%

Gross margin65.4% · median 61.1%

Operating margin-36.8% · median -18.6%

Net margin-96.5% · median -14.0%

Company	Revenue	Growth
MTEX	$107.36M	-5.0%
FTLF	$101.27M	–
SNYRQ	$27.70M	-17.5%
HYEX	$6.29M	+84.1%
GLUC	$88.13K	-70.6%
NTRR	$17.40K	-82.7%

Company

Exchange: OTC
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 3
SEC CIK: 1420108

Advertisement
300 × 250